Neurotoxicity Syndromes
Symptoms, Doctors, Treatments, Advances & More

Neurotoxicity Syndromes Overview

Save information for later
Sign Up

Learn About Neurotoxicity Syndromes

What is the definition of Neurotoxicity Syndromes?
Neurotoxicity syndromes is a term used to describe neurological disorders caused by exposure to toxic substances. Neurotoxicity may occur after exposure to substances such as drugs; chemotherapy; radiation; heavy metals, such as lead or mercury; pesticides; industrial and/or cleaning solvents; petroleum-based products and dispersants; some foods and food additives; and some naturally occurring environmental substances. Exposure to such toxic substances disrupts or kills nerve cells, or neurons, that are responsible for brain and nervous system functions. Neurotoxicity may occur by exposure to toxic substances through ingestion, injection, inhalation, spray, direct skin exposure, or other methods.
What are the symptoms of Neurotoxicity Syndromes?
Symptoms of neurotoxicity may be immediate or delayed. Symptoms of neurotoxicity can include weakness, numbness, headache, memory loss, visual disturbances, cognitive difficulties, behavioral changes, and loss of sexual function, among others.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Neurotoxicity Syndromes?
Treatment for neurotoxicity includes stopping any exposure to the toxic substance and supportive therapy to treat the associated symptoms.
Who are the top Neurotoxicity Syndromes Local Doctors?
Elite in Neurotoxicity Syndromes
Guido A. Cavaletti
Elite in Neurotoxicity Syndromes
Guido A. Cavaletti
Monza, IT 

Guido Cavaletti practices practicing medicine in Monza, Italy. Mr. Cavaletti is rated as an Elite expert by MediFind in the treatment of Neurotoxicity Syndromes. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Peripheral Neuropathy, Neurotoxicity Syndromes, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Polyradiculoneuritis, and Islet Cell Transplantation.

Elite in Neurotoxicity Syndromes
Philippe S. Huot
Elite in Neurotoxicity Syndromes
Philippe S. Huot
60 Leonard Ave, 
Toronto, ON, CA 

Philippe Huot practices practicing medicine in Toronto, Canada. Mr. Huot is rated as an Elite expert by MediFind in the treatment of Neurotoxicity Syndromes. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Drug Induced Dyskinesia, Parkinson's Disease, Movement Disorders, and Neurotoxicity Syndromes.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Neurotoxicity Syndromes
Paola M. Alberti
Elite in Neurotoxicity Syndromes
Paola M. Alberti
Monza, IT 

Paola Alberti practices practicing medicine in Monza, Italy. Ms. Alberti is rated as an Elite expert by MediFind in the treatment of Neurotoxicity Syndromes. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Neurotoxicity Syndromes, Peripheral Neuropathy, Neuralgia, and Colorectal Cancer.

View All Doctors
What are the latest Neurotoxicity Syndromes Clinical Trials?
An Exploratory Clinical Study Evaluate the Safety and Efficacy of Universal Universal Allogeneic CAR-T Cells Targeting CD19 and BCMA in the Treatment of B Cell-Related Autoimmune Disease
An Exploratory Clinical Study Evaluate the Safety and Efficacy of Universal Universal Allogeneic CAR-T Cells Targeting CD19 and BCMA in the Treatment of B Cell-Related Autoimmune Disease
Enrollment Status: Recruiting
Publish Date: April 02, 2026
Intervention Type: Biological
Study Phase: Early Phase 1

Objectives: The primary goals are to evaluate the safety profile, including the incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and to assess clinical response rates at 90 days post-infusion .Follow-up: Subjects will be monitored for pharmacokinetics (cell expansion), pharmacodynamics (B-cell depletion), and long-term safety for up to two years ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
IIT2022-04-Sasine-CAR-T: A Phase 1 Single-arm, Open-label Study to Evaluate the Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
IIT2022-04-Sasine-CAR-T: A Phase 1 Single-arm, Open-label Study to Evaluate the Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Enrollment Status: Recruiting
Publish Date: March 04, 2026
Intervention Type: Biological
Study Phase: Phase 1

Summary: The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate feasibility of collecting the target dose of HSCs from at least 50% of enrolled patients. The study will assess safety based on incidence and severity of...

View All Clinical Trials